BIIB – biogen inc. (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day BIIB SPY QQQ SPX
Date
Time
Symbol
Company Name
Action
%Chg
10/31/2024
04:02 pm
biib
biogen inc.
BEAT
-0.1%
10/30/2024
04:02 pm
biib
biogen inc.
BEAT
-4.0%
10/30/2024
07:46 am
biib
biogen inc.
BEAT
-2.1%
8/2/2024
04:01 pm
biib
biogen inc.
BEAT
-3.5%
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Top News Gainers
10/22 Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies 25.3%
2/5 Form SC 13G/A BIOGEN INC. Filed by: BlackRock Inc. 17.6%
3/12 Form 4 BIOGEN INC. For: Mar 11 Filed by: SHERWIN STEPHEN A 15.1%
3/16 Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World 8.4%
3/2 Biogen Inc (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. 6.2%
7/23 Biogen profit rises 72% on multiple sclerosis therapy sales [Reuters] 4.7%
4/2 Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study 4.3%
3/3 Why Biogen Stock Rose 14.7% in February [The Motley Fool] 4.0%
2/3 Form 8-K BIOGEN INC. For: Jan 28 3.9%
11/22 Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate) 3.7%
Top News Decliners
10/22 Biogen's stock rockets after earnings beat, Alzheimer's treatment heads for regulatory approval process [MarketWatch] -11.9%
2/5 U.S. patent office rules in favor of Biogen over Mylan for MS drug [Reuters] -9.1%
3/7 Is Biogen Inc. (BIIB) A Good Stock To Buy? [Yahoo! Finance News] -5.7%
4/22 Q1/2020 3/31/2020 EPS 9.140 ZacksConsensus 7.740 ActVsEst 1.400 - Beat -5.1%
2/27 Biogen Inc (NASDAQ: BIIB) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -4.9%
3/18 Coronavirus delays Biogen's Spinraza for some patients [Reuters (UK)] -4.5%
1/30 Biogen beats profit estimates on demand for multiple sclerosis drug [Reuters] -4.0%
10/23 Biogen Inc (NASDAQ: BIIB) had its price target raised by analysts at Morgan Stanley from $212.00 to $262.00. They now have an "underweight" rating on the stock. -3.5%
1/30 Biogen Inc (NASDAQ: BIIB) had its "neutral" rating re-affirmed by analysts at Wedbush. -3.2%
10/2 Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders -3.1%

Don’t Miss Out On The Next BIG Stock Move

Thanks for submitting the form.
BIIB – biogen inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
BIIB
SPY
QQQ
SPX
BIIB – biogen inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
BIIB SPY QQQ SPX
Stock Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Stock Stats
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
News
11/21
08:27 am
biib
Low
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Mizuho from $251.00 to $207.00. They now have an "outperform" rating on the stock.
11/20
02:02 pm
biib
Low
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside [Yahoo! Finance]
11/19
01:13 am
biib
Low
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity [Yahoo! Finance]
11/19
01:00 am
biib
Low
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
11/18
07:21 am
biib
Low
Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at Needham & Company LLC to a "hold" rating. They now have a $270.00 price target on the stock.
11/18
07:12 am
biib
Low
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™ [Yahoo! Finance]
11/18
04:37 am
biib
Low
Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now? [Yahoo! Finance]
11/15
10:59 am
biib
Low
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe [Yahoo! Finance]
11/15
08:04 am
biib
Medium
Biogen Inc. (NASDAQ: BIIB) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
10/31/2024
04:02 pm
biib
-0.1%
BEAT
10/30/2024
04:02 pm
biib
-4.0%
BEAT
10/30/2024
07:46 am
biib
-2.1%
BEAT
8/2/2024
04:01 pm
biib
-3.5%
BEAT
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.
11/21
08:07 am
Maintains
Outperform
Outperform
Mizuho
Low
1.3%
11/21
08:07 am
Maintains
Outperform
Outperform
Mizuho
Low
1.3%
11/18
07:21 am
Downgrades
Hold
Needham & Company LLC
Low
-0.3%
11/18
05:07 am
Downgrades
Buy
Hold
Needham
Low
0.1%
11/18
05:07 am
Downgrades
Buy
Hold
Needham
Low
0.1%
11/15
08:04 am
Initiates
Peer Perform
Wolfe Research
Medium
-3.3%
11/15
08:04 am
Initiates
Peer Perform
Wolfe Research
Medium
-3.3%
11/15
07:17 am
Maintains
Outperform
Outperform
Baird
Medium
-3.9%
11/15
07:17 am
Maintains
Outperform
Outperform
Baird
Medium
-3.9%
11/12
01:25 pm
biib
Low
Form SC 13G/A BIOGEN INC. Filed by: VANGUARD GROUP INC
11/7
04:28 pm
biib
Low
Form 4 BIOGEN INC. For: Nov 05 Filed by: ALEXANDER SUSAN H
11/4
04:39 pm
biib
Low
Form 4 BIOGEN INC. For: Nov 01 Filed by: Grogan Jane
11/4
11:20 am
biib
Low
Form SC 13G/A BIOGEN INC. Filed by: VANGUARD GROUP INC
10/30
04:46 pm
biib
Medium
Form 8-K BIOGEN INC. For: Oct 28
10/30
04:32 pm
biib
Medium
Form 10-Q BIOGEN INC. For: Sep 30
10/30
06:56 am
biib
Medium
Form 8-K BIOGEN INC. For: Oct 30
10/16
12:12 pm
biib
Low
Form SC 13G BIOGEN INC. Filed by: STATE STREET CORP
10/7
07:08 pm
biib
Low
Form 3 BIOGEN INC. For: Oct 01 Filed by: Minor Lloyd
Show more
Top News Gainers
10/22 Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies 25.3%
2/5 Form SC 13G/A BIOGEN INC. Filed by: BlackRock Inc. 17.6%
3/12 Form 4 BIOGEN INC. For: Mar 11 Filed by: SHERWIN STEPHEN A 15.1%
3/16 Biogen Foundation Commits $10 Million to Support COVID-19 Relief Efforts in the U.S. and Around the World 8.4%
3/2 Biogen Inc (NASDAQ: BIIB) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. 6.2%
7/23 Biogen profit rises 72% on multiple sclerosis therapy sales [Reuters] 4.7%
4/2 Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study 4.3%
3/3 Why Biogen Stock Rose 14.7% in February [The Motley Fool] 4.0%
2/3 Form 8-K BIOGEN INC. For: Jan 28 3.9%
11/22 Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate) 3.7%
Top News Decliners
10/22 Biogen's stock rockets after earnings beat, Alzheimer's treatment heads for regulatory approval process [MarketWatch] -11.9%
2/5 U.S. patent office rules in favor of Biogen over Mylan for MS drug [Reuters] -9.1%
3/7 Is Biogen Inc. (BIIB) A Good Stock To Buy? [Yahoo! Finance News] -5.7%
4/22 Q1/2020 3/31/2020 EPS 9.140 ZacksConsensus 7.740 ActVsEst 1.400 - Beat -5.1%
2/27 Biogen Inc (NASDAQ: BIIB) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -4.9%
3/18 Coronavirus delays Biogen's Spinraza for some patients [Reuters (UK)] -4.5%
1/30 Biogen beats profit estimates on demand for multiple sclerosis drug [Reuters] -4.0%
10/23 Biogen Inc (NASDAQ: BIIB) had its price target raised by analysts at Morgan Stanley from $212.00 to $262.00. They now have an "underweight" rating on the stock. -3.5%
1/30 Biogen Inc (NASDAQ: BIIB) had its "neutral" rating re-affirmed by analysts at Wedbush. -3.2%
10/2 Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders -3.1%